首页> 美国卫生研究院文献>Pharmaceutics >Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology
【2h】

Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology

机译:使用组织液和微针技术彻底革新治疗药物的监测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While therapeutic drug monitoring (TDM) that uses blood as the biological matrix is the traditional gold standard, this practice may be impossible, impractical, or unethical for some patient populations (e.g., elderly, pediatric, anemic) and those with fragile veins. In the context of finding an alternative biological matrix for TDM, this manuscript will provide a qualitative review on: (1) the principles of TDM; (2) alternative matrices for TDM; (3) current evidence supporting the use of interstitial fluid (ISF) for TDM in clinical models; (4) the use of microneedle technologies, which is potentially minimally invasive and pain-free, for the collection of ISF; and (5) future directions. The current state of knowledge on the use of ISF for TDM in humans is still limited. A thorough literature review indicates that only a few drug classes have been investigated (i.e., anti-infectives, anticonvulsants, and miscellaneous other agents). Studies have successfully demonstrated techniques for ISF extraction from the skin but have failed to demonstrate commercial feasibility of ISF extraction followed by analysis of its content outside the ISF-collecting microneedle device. In contrast, microneedle-integrated biosensors built to extract ISF and perform the biomolecule analysis on-device, with a key feature of not needing to transfer ISF to a separate instrument, have yielded promising results that need to be validated in pre-clinical and clinical studies. The most promising applications for microneedle-integrated biosensors is continuous monitoring of biomolecules from the skin’s ISF. Conducting TDM using ISF is at the stage where its clinical utility should be investigated. Based on the advancements described in the current review, the immediate future direction for this area of research is to establish the suitability of using ISF for TDM in human models for drugs that have been found suitable in pre-clinical experiments.
机译:尽管使用血液作为生物基质的治疗药物监测(TDM)是传统的金标准,但对于某些患者人群(例如老年人,儿科,贫血患者)以及静脉脆弱的患者而言,这种做法可能是不可能,不切实际或不道德的。在为TDM寻找替代生物基质的背景下,该手稿将对以下方面进行定性审查:(1)TDM的原理; (2)TDM的替代矩阵; (3)目前的证据支持在临床模型中将间质液(ISF)用于TDM; (4)使用微针技术收集ISF,该技术可能具有最小的侵入性和无痛性; (5)未来方向。关于在人类中将ISF用于TDM的知识的当前状态仍然很有限。详尽的文献回顾表明,仅研究了少数几种药物(即抗感染药,抗惊厥药和其他杂种药物)。研究已成功地证明了从皮肤中提取ISF的技术,但未能证明ISF提取的商业可行性,然后再分析了ISF收集微针装置外部的含量。相比之下,微针集成的生物传感器可提取ISF并在设备上进行生物分子分析,其关键特征是无需将ISF转移到单独的仪器上,已产生了可喜的结果,需要在临床前和临床中进行验证学习。集成微针生物传感器的最有前途的应用是连续监测来自皮肤ISF的生物分子。使用ISF进行TDM尚处于研究其临床实用性的阶段。基于当前综述中描述的进展,该研究领域的近期方向是建立在人体模型中将ISF用于TDM的适用性,以用于已发现可用于临床前实验的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号